Transparency in physician-industry relationships: State and federal efforts

Pathology Case Reviews

Volumn 17, Issue 4, 2012, Pages 144-147

  MacKey, Tim K ^a,b   Liang, Bryan A ^a,c,d  

^a CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c San Diego Center for Patient Safety   (United States)

^d University of California at San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACT; ADVERTIZING; CONSUMER; GOVERNMENT; HEALTH CARE INDUSTRY; HEALTH CARE POLICY; HUMAN; LAW; MANAGEMENT; MARKETING; MEDICAL FEE; PRIORITY JOURNAL; REVIEW;

EID: 84864245928     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/PCR.0b013e31826750cf     Document Type: Review

References (35)

1. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357(7):673-681. (Pubitemid 47267237)
2. Liang BA, Mackey T. Reforming direct-to-consumer advertising. Nat Biotechnol 2011;29:397-400.
3. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283(3):373-380. (Pubitemid 30051756)
4. Moffatt B, Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 2007;50(1):18-31. (Pubitemid 46185081)
5. Liang BA, Mackey T. Confronting conflict: addressing institutional conflicts of interest in academic medical centers. Am J Law Med 2010;36(1):136-187.
6. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med 2007;356(17):1742-1750. (Pubitemid 46658706)
7. Kaiser. Prescription Drug Trends [Internet]. kff.org. 2010. Available at: http://www.kff.org/rxdrugs/upload/3057-08.pdf.Accessed March 10, 2012.
8. Angell M. Excess in the pharmaceutical industry. CMAJ 2004;171(12):1451-1453. (Pubitemid 39655824)
9. DHHS. Health Care Fraud Prevention and Enforcement Efforts Result in Record-breaking Recoveries Totaling Nearly $4.1 Billion [Internet]. hhs.gov. 2012. Available at: http://www.hhs.gov/news/press/2012pres/02/ 20120214a.html. Accessed April 2, 2012.
10. Mackey T, Liang B. Off-label promotion reform: a legislative proposal addressing vulnerable patient drug access and limiting inappropriate pharmaceutical marketing. Univ Mich J Law Reform 2011;45(1).
11. NCSL. Marketing and Advertising of Pharmaceuticals [Internet]. ncsl.org. Available at: http://www.ncsl.org/issues-research/health/marketing-and- advertising-of-pharmaceuticals.aspx.Accessed March 18, 2012.
12. Lurie P, Ross JS, Rosenbaum AH, et al. Congressional Testimony on State Laws Requiring Disclosure of Pharmaceutical Company Payments to Physicians [Internet]. citizen.org. 2007. Available at:http://www.citizen.org/Page.aspx? pid=740. Accessed April 2, 2012.
13. Ross JS, Lackner JE, Lurie P, et al. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;297(11):1216-1223. (Pubitemid 46469916)
14. California Health and Safety Code §119400Y119402.
15. EOHHS. Background Information about the Code of Conduct [Internet]. mass.gov. Available at: http://www.mass.gov/eohhs/provider/licensing/programs/ pharm-code-of-conduct/background-information-about-thecode-of-conduct.html. Accessed April 3, 2012.
16. Vermont. Disclosures by Manufacturers of Prescription Drugs, Biological Products and Medical Devices [Internet]. Vermont Office of the Attorney General. 2011. Available at: http://www.atg.state.vt.us/issues/pharmaceutical- manufacturer-payment-disclosure.php.Accessed March 28, 2012.
17. Hobson K. Follow-up: Massachusetts Gift Ban Won't Be Repealed [Internet]. blogs.wsj.com. 2010. Available at: http://blogs.wsj.com/health/2010/08/02/ follow-up-massachusetts-gift-ban-wont-be-repealed/.Accessed April 3, 2012.
18. Vermont Sees Drug Companies Reduce Payments To Health Care Providers [Internet]. Vermont Office of the Attorney General. 2011. Available at: http://www.atg.state.vt.us/news/vermont-sees-drugcompanies-reduce-payments-to- health-care-providers.php.Accessed March 28, 2012.
19. Sorrell v. IMS Health Inc, 131 S Ct 2653 (2011).
20. Orszag PR, Emanuel EJ. Health care reform and cost control. N Engl J Med 2010;363(7):601-603.
21. CMS. Federal Register: Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests [Internet]. gpo.gov. 2011.Available at: http://www.gpo.gov/fdsys/pkg/FR-2011-12-19/pdf/2011-32244.pdf. Accessed December 30, 2011.
22. Pew. Federal Reporting Requirements on Payments to Physicians: Impact on State Laws [Internet]. pewhealth.org. 2011. Available at:http://www.pewhealth. org/uploadedFiles/PHG/Supporting-Items/IB-FS-PPP-Sunshine-Act-State-Laws.pdf. Accessed April 2, 2012.
23. Steinman MA, Landefeld CS, Baron RB. Industry support of CMEVare we at the tipping point? N Engl J Med 2012;366(12):1069-1071.
24. Curfman GD, Abel BS, Landers RM. Supreme Court review of the health care reform law. N Engl J Med 2012;366(11):977-979.
25. Liang BA, Mackey TK. Online availability and safety of drugs in shortage: a descriptive study of Internet vendor characteristics. J Med Internet Res 2012;14(1):e27.
26. Liang BA, Mackey T. Direct-to-consumer advertising with interactive Internet media: global regulation and public health issues. JAMA 2011;305(8):824-825.
27. Liang BA, Mackey TK. Prevalence and global health implications of social media in direct-to-consumer drug advertising. J Med Internet Res 2011;13(3):e64.
28. Liang BA, Mackey TK. Vaccine shortages and suspect online pharmacy sellers. Vaccine 2012;30(2):105-108.
29. Liang BA, Lovett KM, Mackey TK. Elder abuse. J Am Geriatr Soc 2012;60(2):398-400.
30. Lovett KM, Liang BA. Direct-to-consumer cardiac screening and suspect risk evaluation. JAMA 2011;305(24):2567-2568.
31. Lovett KM, Liang BA, Mackey TK. Risks of online direct-to-consumer tumor markers for cancer screening. J Clin Oncol 2012;30(13):1411-1414.
32. Lovett KM, Liang BA. Risks of online advertisement of direct-to-consumer thermography for breast cancer screening. Nat Rev Cancer 2011;11(12):827-828.
33. Mackey TK, Liang BA, Lovett KM. Waking up to the risks of online direct-to-consumer advertising of sleep apnea screening tests. J Clin Sleep Med 2012;8(1):5-6.
34. Liang BA, Mackey TK. Creating illicit laparoscopic appendectomy ORs using online sourcing. Am Surg 2012;78:502-503.
35. Liang BA, Mackey T. Quality and safety in medical care: what does the future hold? Arch Pathol Lab Med 2011.;135(11):1425-1431.